ArticlePloS one2025
Association between smoking status and non-alcoholic fatty liver disease.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Treatment Strategies and Novel Therapies.Gut and liver · 2026Review
- Association of a novel Fat-Muscle-BMI Index (FMBI) with NAFLD, liver fibrosis, and atherosclerotic cardiovascular disease risk: a cross-sectional study in 1,592 Chinese adults.BMC gastroenterology · 2026Article
- Evaluation of Liver Fibrosis and Metabolic Risk in Non-Alcoholic Fatty Liver Disease.Journal of pharmacy & bioallied sciences · 2026Article
- Smoking and liver diseases: an updated review of pathogenesis, progression, and therapeutic implications.Clinical and experimental medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe relationship between cigarette smoking and nonalcoholic fatty liver disease (NAFLD) remains controversial. Recent studies have demonstrated that cigarette smoking is a significant risk factor for the development of NAFLD. This study aimed to examine the association between smoking and NAFLD according to smoking status among Korean males, and to examine the relationship between smoking cessation and NAFLD.
methodsThis cross-sectional study included data from 12,241 adult males who underwent health checkups at a university hospital health promotion center between January 2018 and December 2019. Fatty liver was diagnosed using abdominal ultrasonography. The participants were categorized according to self-reported smoking status, pack-years, and period of smoking cessation. Odds ratio (OR) and corresponding 95% confidence interval (CI) for NAFLD were calculated using logistic regression analysis.
resultsAfter adjusting for confounding factors, the OR for NAFLD was 1.190 (95% CI 1.071-1.322, P = .001) among ex-smokers. Among current smokers, the risk for NAFLD increased with an increase in the amount of cigarette smoking (10-20 and ≥20 pack-years versus [vs.] never smoker, adjusted OR [aOR] 1.289 [95% CI 1.107-1.500]; P = .001 and 1.235 [95% CI 1.043-1.461]). The prevalence of NAFLD was inversely associated with the duration of smoking cessation (< 10 years vs. 10-20 years and ≥ 20 years; aOR 0.748 [95% CI 0.638-0.876], P < .001 and 0.750 [95% CI 0.592-0.950], P = .017, respectively).
conclusionCigarette smoking was significantly associated with increased odds of NAFLD, whereas smoking cessation for more than 10 years was associated with decreased odds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.